Category Archives: Research

Take the 2020 PA LGBTQ+ Needs Assessment

CenterLink is working with a coalition of more than 25 LGBTQ organizations across the state of Pennsylvania to collect data for the 2020 PA LGBTQ Needs Assessment. This information will be used to fuel new and existing community-based programs designed to close gaps in service and address the unique health needs of our population.

centerlink logos

We are asking you to take the time to raise your voice for LGBTQ health, and be entered in a raffle to win a gift card now, by taking the 2020 PA LGBTQ Needs Assessment here. People can also participate through a Spanish version here.

Every person who partakes in the survey will be helping Pennsylvania’s department of health learn more about how to promote the health and well-being of LGBTQ people and helping our coalition to build a stronger network of LGBTQ community supports across the state.
Thank you for your participation.

Sharable Link: https://lgbtactionlink.org/take-action/blog/2020-pa-lgbtq-needs-assessment

A more convenient, monthly treatment for HIV cleared a key hurdle

From Science News

People living with HIV are one step closer to having a once-a-month treatment alternative to downing two or more pills a day.

Once-a-month injection of antiretrovirals works just as well as a daily pill regimen, trials show

Once-a-month injection of antiretrovirals works just as well as a daily pill regimen, trials show

There is no cure for HIV, the virus that causes AIDS. But combination antiretroviral therapy, or ART, can effectively halt the replication of the virus, nearly eliminating it from the bloodstream and prolonging life expectancy (SN: 11/15/19). For the therapy to work, though, people must stick to a daily regimen of two or more pills, which experts say can be a challenge for many.

Now, the results of two phase III clinical trials suggest that a monthly shot of antiretroviral drugs works just as well as daily pills, researchers report March 4 in two studies in the New England Journal of Medicine. If approved by regulators, the therapy could be a more convenient treatment for the estimated 1.1 million people living with HIV in the United States.

“From a patient perspective, these results are very positive,” says Elizabeth Tolley, an epidemiologist at FHI 360, a public health nonprofit based in Durham, N.C. Stigma can make people reluctant to keep HIV drugs around the house or to take them each day in front of a loved one, she says. A monthly alternative could be a better option for many.

Read the full article.

Young men unaware of risks of HPV infection and need for HPV vaccination

From Eurekalert.com

Young sexual minority men — including those who are gay, bisexual, queer or straight-identified men who have sex with men — do not fully understand their risk for human papillomavirus (HPV) due to a lack of information from health care providers, according to Rutgers researchers.

Two men standing together. One man has  his arm around the other. Doctors need to expand communication on risks and the importance of vaccination, Rutgers researchers say

A Rutgers study published in the Journal of Community Health, examined what young sexual minority men — a high-risk and high-need population — know about HPV and the HPV vaccine and how health care providers communicate information about the virus and vaccine.

About 79 million Americans are infected with HPV, with about 14 million becoming newly infected each year, according to the Centers for Disease Control and Prevention. As a sexually transmitted infection, HPV can lead to several types of cancer, including anal and penile cancer, and is particularly concerning for sexual minority men due to the high prevalence of HIV and smoking in this community and the low HPV vaccination rates overall among men.

“Particularly in light of the decades-long focus on gay men’s health care as HIV care, there is a missed opportunity for HPV prevention in the community,” said study co-author Caleb LoSchiavo, a doctoral student at the Rutgers School of Public Health.

Read the full article.

Despite ART, Immune System Ages Faster Among People Living With HIV, Study Finds

From thebodypro.com

Today’s powerful antiretroviral therapy (ART) helps fight back HIV infection and restore normal immune function. However, clinical evidence suggests that people with HIV who are virologically suppressed still have higher rates of comorbid viral infections than the general population.

Now, a new study in the Journal of Infectious Diseases suggests that ART does not restore the immune system completely back to normal. Instead, people with HIV may experience “immune amnesia,” in which the immune system slowly loses its capacity to recognize and fight off viral infections introduced during childhood or through a vaccine.

“Even with therapy, there’s something not quite fixed about the immune system,” said lead author Michael Augenbraun, M.D., FACP, FIDSA, who is vice chair of the Department of Medicine and director of the Division of Infectious Diseases at SUNY Downstate Health Sciences University and Kings County Hospital Center.

In the study, Augenbraun and his colleagues compared immune response among a group of 50 HIV-negative women and a group of 50 HIV-positive women on ART with low viral load. Each of these women had been vaccinated against smallpox during childhood, so they should all theoretically have similar levels of lingering protection against the smallpox virus.

Read the full article.

Trust and stigma affect gay couples’ choices on PrEP and PEP

From aidsmap.com

Both relationship-specific and structural factors influence whether coupled gay men living in New York City choose to use pre- and post-exposure prophylaxis (PrEP/PEP) for HIV prevention. Some men – particularly those in monogamous relationships – felt that discussing PrEP and PEP in the context of a relationship could threaten the relationship by raising issues of trust, while others felt that it had the potential to enhance sexual health and satisfaction.

Stigma from the gay community and healthcare providers around promiscuity also presented barriers to PrEP uptake. This qualitative research was conducted by Stephen Bosco, Dr Tyrel Starks and colleagues at City University New York and published in the Journal of Homosexuality.

Gay and bisexual men accounted for 66% of all new HIV diagnoses in the US in 2017. It is estimated that 35-68% of these infections happen within the context of a long-term relationship. This indicates that coupled gay men have the potential to benefit significantly from biomedical prevention strategies, such as PrEP (taken on an ongoing basis) and PEP (taken shortly after a suspected infection). However, only 7% of the potential 1.1 million gay and bisexual men who could benefit from PrEP were prescribed it in 2016. Black and minority men in the US remain most at-risk for HIV infection, while also having the lowest rates of PrEP uptake.

Read the full article.

Unsung heroes: Pittsburgh men, decades-long study impact HIV/AIDS research

From the Triblive.com

As they have for more than three decades, the Pitt Men’s Study leaders gathered with about four dozen men and women. They remembered those who have died and gave thanks for the 1,743 men who have participated in the nation’s longest-running HIV/AIDS research project.

World AIDS Day observance at the Heinz Memorial Chapel—an event sponsored by the Pitt Men’s Study

Charles Rinaldo, a Ph.D. scientist who has led the effort since the virus surfaced here in 1981, walked solemnly down the center aisle with a group of clergy.

“So here we are again to honor our participants,” the soft-spoken Rinaldo said, welcoming the sparse group. “For 35 years now, you have supported our study for HIV/AIDS. … We can’t thank you enough. Without you, there is no study.”

Every six months, year after year, participants have trekked to Oakland to offer blood and bodily fluids. Their alms have become the foundation of hundreds of research projects.

The Pitt study, conducted in the halls of the university where Jonas Salk developed the world’s first polio vaccine, began before the affliction that has killed an estimated 32 million people worldwide even had a name: human immunodeficiency virus. Or simply, HIV.
Neither the virus nor its final, deadly stage — acquired immunodeficiency syndrome, or AIDS — dominates the news and national fears as they did decades ago. Yet around the world, about 38 million people remain infected. Many are living longer lives thanks to lifesaving, though expensive, medical treatments. But there is no cure — yet.
Worldwide, an estimated 1.7 million people became infected with HIV last year. Another 770,000 died from AIDS-related illnesses.

In the United States, just more than 1 million people are believed to be living with HIV. Although the number of new infections has declined dramatically, nearly 40,000 in the U.S. still contract HIV every year. And about 16,000 people died from AIDS in the United States in 2016.

Because of that, work on the Pitt Men’s Study continues.

Read the full article.

Studies firmly establish “undetectable equals untransmittable”

From NIH.gov

Extensive evidence from HIV prevention research studies has firmly established that “Undetectable Equals Untransmittable,” or U=U. This means that people living with HIV who achieve and maintain an undetectable viral load — the amount of virus in their blood — by taking antiretroviral therapy (ART) as prescribed do not sexually transmit HIV to others. The U.S. Centers for Disease Control and Prevention estimates this strategy is 100% effective against the sexual transmission of HIV.

Now, a new study of nearly 112,000 men who have sex with men in the United States has found increasing acceptance of the U=U message in this population. Overall, 54% of HIV-negative participants and 84% of participants with HIV correctly identified U=U as accurate. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Study results were published online in the Journal of Acquired Immune Deficiency Syndromes.

“U=U has been validated repeatedly by numerous studies as a safe and effective means of preventing the sexual transmission of HIV,” said Anthony S. Fauci, M.D., NIAID Director. “The increased understanding and acceptance of U=U is encouraging because HIV treatment as prevention is a foundation of efforts to end the epidemic in the United States and around the world. This public health message has the power to reduce stigma, protect the health of people living with HIV and prevent sexual transmission of HIV to others.”

Read the full article.